Nicotine treatment improves toll-like receptor 2 and toll-like receptor 9 responsiveness in active pulmonary sarcoidosis

Chest

Volumn 143, Issue 2, 2013, Pages 461-470

  Julian, Mark W ^a   Shao, Guohong ^a   Schlesinger, Larry S ^a   Huang, Qin ^a   Cosmar, David G ^a   Bhatt, Nitin Y ^a   Culver, Daniel A ^b   Baughman, Robert P ^c   Wood, Karen L ^a   Crouser, Elliott D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; IMMUNOSUPPRESSIVE AGENT; LIGAND; NICOTINE; NUCLEOTIDE OLIGOMERIZATION DOMAIN LIKE RECEPTOR LIGAND; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CELL; CD4+ CD25- FOXP3+ REGULATORY T LYMPHOCYTE; CD4+ FOXP3+ REGULATORY T LYMPHOCYTE; CELL SURFACE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FOXP3+ REGULATORY T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG SARCOIDOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT;

EID: 84874063489     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-0383     Document Type: Article

References (54)

1. Paramothayan NS, Lasserson TJ, Jones PW. Corticosteroids for pulmonary sarcoidosis. Cochrane Database Syst Rev. 2005;(2): CD001114.
2. Cox CE, Donohue JF, Brown CD, Kataria YP, Judson MA. Health-related quality of life of persons with sarcoidosis. Chest. 2004; 125 (3): 997-1004.
3. Moller DR, Forman JD, Liu MC, et al. Enhanced expression of IL-12 associated with Th1 cytokine profiles in active pulmonary sarcoidosis. J Immunol. 1996; 156 (12): 4952-4960.
4. Rastogi R, Du W, Ju D, et al. Dysregulation of p38 and MKP-1 in response to NOD1/TLR4 stimulation in sarcoid bronchoalveolar cells. Am J Respir Crit Care Med. 2011; 183 (4): 500-510.
5. Miyara M, Amoura Z, Parizot C, et al. The immune paradox of sarcoidosis and regulatory T cells. J Exp Med. 2006; 203 (2): 359-370.
6. Rappl G, Pabst S, Riemann D, et al. Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. Clin Immunol. 2011; 140 (1): 71-83.
7. Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010; 182 (4): 540-548.
8. Wang H, Yu M, Ochani M, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of infl ammation. Nature. 2003; 421 (6921): 384-388.
9. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-infl ammatory system by nicotine attenuates neuroinfl ammation via suppression of Th1 and Th17 responses. J Immunol. 2009; 183 (10): 6681-6688.
10. Wang DW, Zhou RB, Yao YM, et al. Stimulation of a 7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4 1 CD25 1 regulatory T cells in mice in vitro. J Pharmacol Exp Ther. 2010; 335 (3): 553-561.
11. Geng Y, Savage SM, Razani-Boroujerdi S, Sopori ML. Effects of nicotine on the immune response. II. Chronic nicotine treatment induces T cell anergy. J Immunol. 1996; 156 (7): 2384-2390.
12. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol. 2002; 2 (5): 372-377.
13. Valeyre D, Soler P, Clerici C, et al. Smoking and pulmonary sarcoidosis: effect of cigarette smoking on prevalence, clinical manifestations, alveolitis, and evolution of the disease. Thorax. 1988; 43 (7): 516-524.
14. Shang S, Ordway D, Henao-Tamayo M, et al. Cigarette smoke increases susceptibility to tuberculosis-evidence from in vivo and in vitro models. J Infect Dis. 2011; 203 (9): 1240-1248.
15. Yoshikawa H, Kurokawa M, Ozaki N, et al. Nicotine inhibits the production of proinflammatory mediators in human mono cytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol. 2006; 146 (1): 116-123.
16. Tracey KJ. Refl ex control of immunity. Nat Rev Immunol. 2009; 9 (6): 418-428.
17. Man SM, Kaakoush NO, Mitchell HM. The role of bacteria and pattern-recognition receptors in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2011; 8 (3): 152-168.
18. Wikén M, Grunewald J, Eklund A, Wahlström J. Higher monocyte expression of TLR2 and TLR4, and enhanced proinfl ammatory synergy of TLR2 with NOD2 stimulation in sarcoidosis. J Clin Immunol. 2009; 29 (1): 78-89.
19. Lin HH, Ezzati M, Chang HY, Murray M. Association between tobacco smoking and active tuberculosis in Taiwan: prospective cohort study. Am J Respir Crit Care Med. 2009; 180 (5): 475-480.
20. Newman LS, Rose CS, Bresnitz EA, et al; ACCESS Research Group. A case control etiologic study of sarcoidosis: environmental and occupational risk factors. Am J Respir Crit Care Med. 2004; 170 (12): 1324-1330.
21. Warren CPW. Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax. 1977; 32 (5): 567-569.
22. Baldwin CI, Todd A, Bourke S, Allen A, Calvert JE. Pigeon fanciers' lung: effects of smoking on serum and salivary antibody responses to pigeon antigens. Clin Exp Immunol. 1998; 113 (2): 166-172.
23. Ingram JR, Rhodes J, Evans BK, Thomas GA. Nicotine enemas for active Crohn's colitis: an open pilot study. Gastroenterol Res Pract. 2008;2008:237185.
24. Ingram JR, Thomas GA, Rhodes J, et al. A randomized trial of nicotine enemas for active ulcerative colitis. Clin Gastroenterol Hepatol. 2005; 3 (11): 1107-1114.
25. Lindblad SS, Mydel P, Jonsson IM, Senior RM, Tarkowski A, Bokarewa M. Smoking and nicotine exposure delay development of collagen-induced arthritis in mice. Arthritis Res Ther. 2009; 11 (3): R88.
26. van Maanen MA, Lebre MC, van der Poll T, et al. Stimulation of nicotinic acetylcholine receptors attenuates collageninduced arthritis in mice. Arthritis Rheum. 2009; 60(1): 114-122.
27. Blanchet MR, Israël-Assayag E, Cormier Y. Inhibitory effect of nicotine on experimental hypersensitivity pneumonitis in vivo and in vitro. Am J Respir Crit Care Med. 2004; 169(8): 903-909.
28. American Thoracic Society Statement on Sarcoidosis. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granuloma tous Disorders (WASOG) adopted by the ATS Board of Direc tors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999; 160 (2): 736-755.
29. Baughman RP. Pulmonary sarcoidosis. Clin Chest Med. 2004; 25 (3): 521-530., vi.
30. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest. 1999; 115 (4): 1158-1165.
31. DiFranza J, Ursprung WW, Lauzon B, et al. A systematic review of the Diagnostic and Statistical Manual diagnostic criteria for nicotine dependence. Addict Behav. 2010; 35 (5): 373-382.
32. Thurm CW, Halsey JF. Measurement of cytokine production using whole blood. Curr Protoc Immunol. 2005;Chapter 7:Unit 7.18B.
33. Hays JT, Ebbert JO. Adverse effects and tolerability of medications for the treatment of tobacco use and dependence. Drugs. 2010; 70 (18): 2357-2372.
34. Sweiss NJ, Salloum R, Gandhi S, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS ONE. 2010; 5 (2): e9088.
35. Minshall EM, Tsicopoulos A, Yasruel Z, et al. Cytokine mRNA gene expression in active and nonactive pulmonary sarcoidosis. Eur Respir J. 1997; 10 (9): 2034-2039.
36. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988; 85 (14): 5274-5278.
37. DeGraff AC Jr. Pharmacologic therapy for nicotine addiction. Chest. 2002; 122 (2): 392-394.
38. Fiore MC, Smith SS, Jorenby DE, Baker TB. The effectiveness of the nicotine patch for smoking cessation. A meta-analysis. JAMA. 1994; 271 (24): 1940-1947.
39. Tukiainen H, Vaara J, Syrjänen K, Terho EO. Granulomatous gastritis as a diagnostic problem between sarcoidosis and other granulomatous disorders. Sarcoidosis. 1988; 5 (1): 66-67.
40. de Jonge WJ, van der Zanden EP, The FO, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol. 2005; 6 (8): 844-851.
41. Marrero MB, Bencherif M. Convergence of alpha 7 nicotinic acetylcholine receptor-activated pathways for anti-apoptosis and anti-infl ammation: central role for JAK2 activation of STAT3 and NF-kappaB. Brain Res. 2009; 1256: 1-7.
42. Lee NS, Barber L, Kanchwala A, et al. Low levels of NF-k B/p65 mark anergic CD4 1 T cells and correlate with disease severity in sarcoidosis. Clin Vaccine Immunol. 2011; 18 (2): 223-234.
43. Morell F, Levy G, Orriols R, Ferrer J, De Gracia J, Sampol G. Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis. Chest. 2002; 121(4): 1239-1244.
44. Demirkok SS, Basaranoglu M, Coker E, Karayel T. Seasonality of the onset of symptoms, tuberculin test anergy and Kveim positive reaction in a large cohort of patients with sarcoidosis. Respirology. 2007; 12 (4): 591-593.
45. Gupta D, Chetty M, Kumar N, Aggarwal AN, Jindal SK. Anergy to tuberculin in sarcoidosis is not influenced by high prevalence of tuberculin sensitivity in the population. Sarcoidosis Vasc Diffuse Lung Dis. 2003; 20 (1): 40-45.
46. Veltkamp M, Van Moorsel CH, Rijkers GT, Ruven HJ, Van Den Bosch JM, Grutters JC. Toll-like receptor (TLR)-9 genetics and function in sarcoidosis. Clin Exp Immunol. 2010; 162 (1): 68-74.
47. Song Z, Marzilli L, Greenlee BM, et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J Exp Med. 2005; 201 (5): 755-767.
48. Grosser M, Luther T, Fuessel M, Bickhardt J, Magdolen V, Baretton G. Clinical course of sarcoidosis in dependence on HLA-DRB1 allele frequencies, infl ammatory markers, and the presence of M. tuberculosis DNA fragments. Sarcoidosis Vasc Diffuse Lung Dis. 2005; 22 (1): 66-74.
49. Chen ES, Song Z, Willett MH, et al. Serum amyloid A regulates granulomatous infl ammation in sarcoidosis through Toll-like receptor-2. Am J Respir Crit Care Med. 2010; 181(4): 360-373.
50. Mathew S, Bauer KL, Fischoeder A, Bhardwaj N, Oliver SJ. The anergic state in sarcoidosis is associated with diminished dendritic cell function. J Immunol. 2008; 181 (1): 746-755.
51. Zelenay S, Lopes-Carvalho T, Caramalho I, Moraes-Fontes MF, Rebelo M, Demengeot J. Foxp3 1 CD25-CD4 T cells constitute a reservoir of committed regulatory cells that regain CD25 expression upon homeostatic expansion. Proc Natl Acad Sci U S A. 2005; 102 (11): 4091-4096.
52. Gupta D, Kumar S, Aggarwal AN, Verma I, Agarwal R. Interferon gamma release assay (QuantiFERON-TB Gold In Tube) in patients of sarcoidosis from a population with high prevalence of tuberculosis infection. Sarcoidosis Vasc Diffuse Lung Dis. 2011; 28 (2): 95-101.
53. Centers for Disease Control and Prevention. Tuberculosis. Centers for Disease Control and Prevention website. http://www.cdc.gov/tb/statistics/ default.htm. Accessed June 4, 2012.
54. Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE. Clinical significance of increased CD4 1 CD25-Foxp3 1 T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis. 2008; 67 (7): 1037-1040.